^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    AiRuiLi (adebrelimab)

    i
    Other names: SHR-1316, SHR 1316, HTI-1088, HTI-1316, HTI1088, HTI 1088, HTI 1316, HTI1316, SHR1316
    Associations

    News

    Trials
    Company:
    Jiangsu Hengrui Pharma
    Drug class:
    PD-L1 inhibitor
    Related drugs:
    Associations

    News

    Trials
    8d
    Neoadjuvant Adebrelimab Plus CRT for Locally Advanced Thymic Carcinoma (clinicaltrials.gov)
    P2, N=31, Not yet recruiting, Shanghai Chest Hospital
    New P2 trial
    |
    cisplatin • albumin-bound paclitaxel • AiRuiLi (adebrelimab)
    14d
    Study of Multi-mode Thermal Therapy Combined With Immunotherapy In Patients With HER2-negative Breast Cancer With Liver Metastases (clinicaltrials.gov)
    P2, N=30, Not yet recruiting, Fudan University
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    Keytruda (pembrolizumab) • trastuzumab rezetecan (SHR-A1811) • Jiataile (sacituzumab tirumotecan) • AiRuiLi (adebrelimab)
    14d
    DAWN trial: a prospective, multicenter, single-arm phase II study of neoadjuvant disitamab vedotin (RC48) in combination with adebrelimab, apatinib, and S-1 for locally advanced HER2-positive gastric cancer. (PubMed, J Gastrointest Oncol)
    We hypothesize that the combination of these four therapeutic strategies could significantly enhance treatment efficacy in HER2-positive gastric cancer, particularly in combined positive score (CPS) PD-L1-negative patients. This study was registered at ClinicalTrials.gov (Identifier: NCT06385873).
    P2 data • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    PD-L1 expression • HER-2 positive • HER-2 expression • PD-L1 negative • EGFR positive
    |
    AiTan (rivoceranib) • Aidixi (disitamab vedotin) • AiRuiLi (adebrelimab)
    14d
    A Phase III Study of HS-20093 Injection Combined With Adebrelimab Versus Docetaxel in Previously Treated Patients With Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Without Actionable Genomic Alterations (clinicaltrials.gov)
    P3, N=450, Not yet recruiting, Hansoh BioMedical R&D Company
    New P3 trial
    |
    docetaxel • AiRuiLi (adebrelimab) • risvutatug rezetecan (GSK5764227)
    17d
    A Study Testing Emactinib Sulfate With Chemotherapy and Immunotherapy Before Surgery for Advanced Head and Neck Cancer (clinicaltrials.gov)
    P2, N=76, Recruiting, Second Affiliated Hospital, School of Medicine, Zhejiang University
    New P2 trial
    |
    CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2)
    |
    cisplatin • albumin-bound paclitaxel • AiRuiLi (adebrelimab)
    19d
    A Randomized, Double-blind, Placebo-controlled, Multicenter Phase II/III Clinical Study of Adebrelimab in Combination With SHR-8068 and Chemoradiotherapy as Perioperative Therapy for Locally Advanced Rectal Cancer (clinicaltrials.gov)
    P2/3, N=165, Not yet recruiting, Suzhou Suncadia Biopharmaceuticals Co., Ltd.
    New P2/3 trial
    |
    CS1002 (ipilimumab biosimilar) • AiRuiLi (adebrelimab)
    21d
    Time-of-Day of Immunotherapy Infusion in Neoadjuvant Immunochemotherapy for Thoracic ESCC (clinicaltrials.gov)
    P2, N=90, Not yet recruiting, Tang-Du Hospital
    New P2 trial
    |
    cisplatin • albumin-bound paclitaxel • AiRuiLi (adebrelimab)
    23d
    A Trial of SHR-A2102 With Adebrelimab in Locally Advanced or Metastatic Urothelial Carcinoma (clinicaltrials.gov)
    P3, N=462, Recruiting, Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    PD-L1 (Programmed death ligand 1) • NECTIN4 (Nectin Cell Adhesion Molecule 4)
    |
    PD-L1 expression
    |
    cisplatin • carboplatin • gemcitabine • SHR-A2102 • AiRuiLi (adebrelimab)
    26d
    Induction Immunochemotherapy Followed by Concurrent Chemoradiotherapy in Patients With ESCC. (clinicaltrials.gov)
    P2, N=60, Recruiting, Tianjin Medical University Cancer Institute and Hospital | Not yet recruiting --> Recruiting | Trial primary completion date: Jun 2025 --> Jun 2026
    Enrollment open • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    carboplatin • albumin-bound paclitaxel • oxaliplatin • AiRuiLi (adebrelimab)
    26d
    Neoadjuvant Adebrelimab Plus Chemotherapy for Esophageal Cancer: A Clinical Study (clinicaltrials.gov)
    P2, N=42, Recruiting, The Affiliated Hospital of Putian University
    New P2 trial
    |
    cisplatin • albumin-bound paclitaxel • AiRuiLi (adebrelimab)
    29d
    A Real-World Study Evaluating the Efficacy and Safety of Adebrelimab in Patients With Advanced SCLC (clinicaltrials.gov)
    P=N/A, N=500, Recruiting, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
    New trial • Real-world evidence
    |
    AiRuiLi (adebrelimab)
    30d
    Adebrelimab Combined With Chemotherapy for the Esophageal Squamous Cell Carcinoma (clinicaltrials.gov)
    P=N/A, N=25, Recruiting, The Second Hospital of Shandong University
    New trial
    |
    cisplatin • carboplatin • albumin-bound paclitaxel • AiRuiLi (adebrelimab)